Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (avaa uuden ikkunan)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Lähde‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Arkistoitu‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (avaa uuden ikkunan)

Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond? (avaa uuden ikkunan)

Banan M.

Lähde‎: Ann Hematol 2013;92(3):289-99.

Arkistoitu‎: PubMed 23318979

DOI‎: 10.1007/s00277-012-1671-3

https://www.ncbi.nlm.nih.gov/pubmed/23318979 (avaa uuden ikkunan)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (avaa uuden ikkunan)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Lähde‎: Transfusion 2007;47(10):1830-6.

Arkistoitu‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (avaa uuden ikkunan)

Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease. (avaa uuden ikkunan)

Fucharoen S, Siritanaratkul N, Winichagoon P, Chowthaworn J, Siriboon W, Muangsup W, Chaicharoen S, Poolsup N, Chindavijak B, Pootrakul P, Piankijagum A, Schechter AN, Rodgers GP.

Lähde‎: Blood 1996;87(3):887-92.

Arkistoitu‎: PubMed 8562958

https://www.ncbi.nlm.nih.gov/pubmed/8562958 (avaa uuden ikkunan)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (avaa uuden ikkunan)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Lähde‎: Iran J Blood Cancer 2009;1(4):147-50.

Arkistoitu‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (avaa uuden ikkunan)

Hydroxyurea as a first-line treatment of extramedullary hematopoiesis in patients with beta thalassemia: Four case reports. (avaa uuden ikkunan)

Karimi M, Cohan N, Pishdad P.

Lähde‎: Hematology 2015;20(1):53-7.

Arkistoitu‎: PubMed 24717020

DOI‎: 10.1179/1607845414Y.0000000168

https://www.ncbi.nlm.nih.gov/pubmed/24717020 (avaa uuden ikkunan)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (avaa uuden ikkunan)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Lähde‎: Int J Hematol 2012;95(1):51-6.

Arkistoitu‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (avaa uuden ikkunan)

Report on Patients with Non Transfusion-Dependent β-Thalassemia Major Being Treated with Hydroxyurea Attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013. (avaa uuden ikkunan)

Kosaryan M, Karami H, Zafari M, Yaghobi N.

Lähde‎: Hemoglobin 2014;38(2):115-8.

Arkistoitu‎: PubMed 24471558

DOI‎: 10.3109/03630269.2013.869229

https://www.ncbi.nlm.nih.gov/pubmed/24471558 (avaa uuden ikkunan)

Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. (avaa uuden ikkunan)

Musallam KM, Taher AT, Cappellini MD, Sankaran VG.

Lähde‎: Blood 2013;121(12):2199-212.

Arkistoitu‎: PubMed 23315167

DOI‎: 10.1182/blood-2012-10-408021

https://www.ncbi.nlm.nih.gov/pubmed/23315167 (avaa uuden ikkunan)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (avaa uuden ikkunan)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Lähde‎: Sci Rep. 2022;12(1):2752.

Arkistoitu‎: PubMed 35177777

DOI‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (avaa uuden ikkunan)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (avaa uuden ikkunan)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Lähde‎: Haematologica 2004;89(10):1172-8.

Arkistoitu‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (avaa uuden ikkunan)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (avaa uuden ikkunan)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Lähde‎: Arch Iran Med 2009;12(3):295-7.

Arkistoitu‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (avaa uuden ikkunan)

Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy. (avaa uuden ikkunan)

Bourantas K, Makrydimas G, Georgiou J, Tsiara S, Lolis D.

Lähde‎: Eur J Haematol 1996;56(5):326-8.

Arkistoitu‎: PubMed 8641410

https://www.ncbi.nlm.nih.gov/pubmed/8641410 (avaa uuden ikkunan)

Induction of fetal hemoglobin synthesis with recombinant human erythropoietin in anemic patients with heterozygous beta-thalassemia during pregnancy. (avaa uuden ikkunan)

Breymann C, Fibach E, Visca E, Huettner C, Huch A, Huch R.

Lähde‎: J Matern Fetal Med 1999;8(1):1-7.

Arkistoitu‎: PubMed 10052837

DOI‎: 10.1002/(SICI)1520-6661(199901/02)8:1<1::AID-MFM1>3.0.CO;2-O

https://www.ncbi.nlm.nih.gov/pubmed/10052837 (avaa uuden ikkunan)

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (avaa uuden ikkunan)

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

Lähde‎: Acta Haematol 2004;111(4):189-95.

Arkistoitu‎: PubMed 15153710

DOI‎: 10.1159/000077551

https://www.ncbi.nlm.nih.gov/pubmed/15153710 (avaa uuden ikkunan)

Recombinant human erythropoietin therapy in a transfusion-dependent β-thalassemia major patient. (avaa uuden ikkunan)

Makis AC, Chaliasos N, Hatzimichael EC, Bourantas KL.

Lähde‎: Ann Hematol 2001;80(8):492-5.

Arkistoitu‎: PubMed 11563599

https://www.ncbi.nlm.nih.gov/pubmed/11563599 (avaa uuden ikkunan)

Fetal globin induction--can it cure beta thalassemia? (avaa uuden ikkunan)

Perrine SP.

Lähde‎: Hematology Am Soc Hematol Educ Program 2005:38-44.

Arkistoitu‎: PubMed 16304357

DOI‎: 10.1182/asheducation-2005.1.38

https://www.ncbi.nlm.nih.gov/pubmed/16304357 (avaa uuden ikkunan)